AbbVie vs Johnson & Johnson: a complete comparison of OVR ratings, fundamentals, volatility, and characteristics.
ABBV is rated 83 OVR (A-Tier (Strong)) — AbbVie navigated the Humira patent expiry by growing Skyrizi and Rinvoq fast enough to replace it. T
JNJ is rated 85 OVR (A-Tier (Strong)) — Johnson & Johnson combines pharmaceuticals and medical devices. It has raised its dividend for 62 co
| METRIC | ABBV (AbbVie) | JNJ (Johnson & Johnson) |
|---|---|---|
| OVR Rating | 83 | 85 |
| Tier | A-Tier (Strong) | A-Tier (Strong) |
| Momentum | 55/100 | 45/100 |
| Stability | 85/100 | 92/100 |
| Value Score | 72/100 | 75/100 |
| Revenue Growth | +4% | +5% |
| P/E Ratio | 16x | 14x |
| Beta (Volatility) | 0.65 | 0.45 |
| Market Cap | $330B | $380B |
| Dividend Yield | 4.0% | 3.3% |
| S&P 500 | Yes | Yes |
| NFL Comparison | Frank Gore | Frank Gore |
| Sector | Healthcare | Healthcare |
AbbVie navigated the Humira patent expiry by growing Skyrizi and Rinvoq fast enough to replace it. This is exceptional drug portfolio management. High dividend yield with growing coverage.
Johnson & Johnson combines pharmaceuticals and medical devices. It has raised its dividend for 62 consecutive years — one of the longest streaks of any public company.
Explore both on MarketMVP
Free platform · Sports-style player ratings for every stock
OPEN MARKETMVP FREE →Educational purposes only. MarketMVP OVR scores, tiers, and athlete comparisons are proprietary educational tools — not financial advice, investment ratings, or recommendations to buy or sell any security. Always conduct your own research. Full disclaimer